Adma Biologics (ADMA) Surpasses Market Returns: Some Facts Worth KnowingZacks Investment Research · 5 days ago
ADMA Biologics Announces Peer-Reviewed Publication Highlighting New Data From Its Optimized, Proprietary IVIG Manufacturing ProcessGlobeNewsWire · Oct 15, 2026
Wall Street Bulls Look Optimistic About Adma Biologics (ADMA): Should You Buy?Zacks Investment Research · Oct 12, 2026
ADMA Biologics (NASDAQ:ADMA) & Myriad Genetics (NASDAQ:MYGN) Critical AnalysisDefense World · Oct 12, 2026
Adma Biologics (ADMA) Advances While Market Declines: Some Information for InvestorsZacks Investment Research · Oct 8, 2026
ADMA Biologics Inc (ADMA) is Attracting Investor Attention: Here is What You Should KnowZacks Investment Research · Oct 8, 2026ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These specialized products are engineered to address immune system disorders and infectious diseases, catering to markets across the United States and internationally. Their current product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) treatments prescribed for primary humoral immunodeficiency (PI).
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 5, 2026 | $0.16 | $0.16 | Miss |
| May 6, 2026 | $0.19 | $0.19 | Miss |
| Feb 25, 2026 | $0.19 | $0.20 | Beat |
| Nov 5, 2025 | $0.16 | $0.16 | Beat |
| Aug 6, 2025 | $0.14 | $0.15 | Beat |
| May 7, 2025 | $0.16 | $0.14 | Miss |